Last reviewed · How we verify
Synflorix™( GSK1024850A)
Synflorix is a pneumococcal conjugate vaccine that stimulates the body's immune response to Streptococcus pneumoniae.
Synflorix is a pneumococcal conjugate vaccine that stimulates the body's immune response to Streptococcus pneumoniae. Used for Prevention of invasive pneumococcal disease caused by Streptococcus pneumoniae serotypes included in the vaccine.
At a glance
| Generic name | Synflorix™( GSK1024850A) |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Conjugate vaccine |
| Modality | Biologic |
| Therapeutic area | Infectious Diseases |
| Phase | Phase 3 |
Mechanism of action
It works by introducing specific polysaccharide antigens from the pneumococcus bacteria to the immune system, which then mounts a targeted response to fight off future infections. This vaccine is designed to provide long-term protection against invasive pneumococcal disease.
Approved indications
- Prevention of invasive pneumococcal disease caused by Streptococcus pneumoniae serotypes included in the vaccine
Common side effects
- Pain, redness, swelling, or bruising at the injection site
- Fever
- Fatigue
Key clinical trials
- Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6 to 10 Weeks of Age (PHASE3)
- Primary Vaccination Study With GSK Biologicals' Pneumococcal Vaccine in Healthy Infants in Vietnam (PHASE3)
- Co-administration of Pneumococcal Conjugate Vaccine With DTPa-IPV-Hib Versus Co-administration With DTPa-HBV-IPV/Hib (PHASE3)
- Prophylactic Antipyretic Treatment in Children Receiving Booster Dose of Pneumococcal Conjugate Vaccine GSK1024850A (PHASE3)
- Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate Vaccine (PHASE3)
- Pneumococcal Vaccine Booster Study in Healthy Children 12-18 Mths Old Previously Primed With the Same Vaccines (PHASE3)
- Assess Reacto- and Immunogenicity of Pneumococcal Conjugate Vaccine When Given as Booster or a 2 Dose Catch up Schedule (PHASE2)
- Study to Evaluate the Safety and Immunogenicity of a 10-valent Pneumococcal Conjugate Vaccine in Preterm Infants (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Synflorix™( GSK1024850A) CI brief — competitive landscape report
- Synflorix™( GSK1024850A) updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI